STOCK TITAN

Aligos Therapeutics (ALGS) Stock Price, News & Analysis

ALGS NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
73 252 sessions, November 18, 2025 to November 18, 2026
Largest daily move
+36.9% close of August 10, 2026
1-year change
-83.6% closing prices, November 18, 2025 to November 18, 2026
1-month change
-73.3% closing prices, October 16, 2026 to November 18, 2026

Company Description

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company focused on developing therapies for liver and viral diseases. According to the company, its mission is to improve patient outcomes by advancing best-in-class therapeutics in areas of high unmet medical need, including chronic hepatitis B virus (HBV) infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.

Aligos describes itself as applying a science-driven approach and deep research and development expertise to a purpose-built pipeline. This pipeline includes multiple investigational drug candidates that target distinct biological mechanisms involved in liver and viral diseases, with an emphasis on chronic HBV and metabolic liver conditions.

Focus on chronic hepatitis B virus (HBV)

A central program at Aligos is pevifoscorvir sodium (also referred to as "pevy"), which the company characterizes as a potent oral small molecule capsid assembly modulator (CAM-E) under investigation for the treatment of chronic HBV infection. Phase 1 studies of pevifoscorvir sodium have evaluated single and multiple daily doses, including longer-term dosing up to 96 weeks. The company reports that these studies have shown antiviral activity with sustained reductions in HBV DNA and other viral biomarkers, and that pevifoscorvir sodium has been well-tolerated in the studied populations.

Aligos has initiated a Phase 2 study called B-SUPREME (NCT06963710) in untreated HBeAg-positive and HBeAg-negative adults with chronic HBV infection. The study is designed as a randomized, double-blind, active-controlled, multicenter trial comparing pevifoscorvir sodium monotherapy with tenofovir disoproxil fumarate. The company states that the trial evaluates virologic endpoints such as HBV DNA levels below the lower limit of quantification, as well as safety, pharmacokinetics, and additional HBV biomarkers, including HBV antigens.

In presentations at scientific meetings, Aligos has highlighted data suggesting that pevifoscorvir sodium may have effects across the HBV lifecycle. The company has reported rapid, profound, and durable reductions in HBV DNA in both HBeAg-positive and HBeAg-negative subjects in Phase 1 monotherapy cohorts, with suppression maintained over extended treatment periods. It has also described concurrent reductions in HBV antigens and RNA, and preclinical data on ALG-001075, the active parent moiety of pevifoscorvir sodium, indicating prevention of cccDNA formation and HBV DNA integration in vitro.

Programs in obesity and MASH

Beyond HBV, Aligos is developing ALG-055009, which it describes as a potent small molecule thyroid hormone receptor beta (THR-β) agonist under investigation for the treatment of obesity and MASH. The company has presented nonclinical in vivo data in diet-induced obese mouse models showing that ALG-055009, when combined with incretin receptor agonists such as semaglutide or tirzepatide, produced synergistic body weight loss compared with monotherapy. According to Aligos, the additional weight loss in combination regimens was primarily due to increased fat mass reduction without a significant impact on lean mass or food consumption relative to incretin receptor agonist monotherapy.

These preclinical findings support Aligos’ view that ALG-055009 may have a role in combination regimens in the cardiometabolic space, particularly where incretin receptor agonists are used. The company has also indicated that it is evaluating options to fund continued development of ALG-055009, including potential out-licensing.

Additional liver and viral disease research

Aligos reports ongoing early-stage and preclinical work in other liver and viral disease programs. These include antisense oligonucleotide (ASO) approaches targeting HBV and hepatitis delta virus (HDV), as well as preclinical short interfering RNA (siRNA) molecules targeting human HSD17beta13 for the potential treatment of MASH. The company has presented data on these programs at scientific conferences, emphasizing continued exploration of next-generation therapies in liver and viral disease.

In the area of coronaviruses, Aligos identifies coronaviruses as one of the disease categories addressed by its pipeline. Aligos Therapeutics, Inc. focuses its therapeutics on coronaviruses, HBV, obesity, and MASH, with programs emphasizing HBV and metabolic liver disease.

Corporate profile and listing

Aligos Therapeutics, Inc. is incorporated in Delaware and lists its common stock on The Nasdaq Stock Market LLC (Nasdaq Capital Market) under the ticker symbol ALGS. The company is based in South San Francisco, California, a location noted in its SEC filings as the site of its principal offices. As a clinical stage biotechnology company, Aligos does not describe itself as having approved commercial products in the provided materials; instead, it focuses on the development and clinical evaluation of its investigational candidates.

The company has adopted equity incentive plans and inducement plans to support hiring and retention. For example, Aligos has disclosed a 2020 Incentive Award Plan and subsequent amendments to increase the number of shares reserved under the plan, as well as a 2024 Inducement Plan used for equity awards to new employees under Nasdaq Listing Rule 5635(c)(4). These plans reflect the company’s use of stock-based compensation as part of its overall employment and incentive structure.

Regulatory and scientific engagement

Aligos reports that pevifoscorvir sodium has a regulatory path acknowledged by multiple regulatory authorities, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the National Medical Products Administration (NMPA) in China, for studies utilizing a chronic suppressive pathway in HBV. The company regularly presents data from its programs at scientific and medical conferences, such as AASLD’s The Liver Meeting and the HEP-DART meeting, and posts related materials in its posters and presentations resources.

The company’s disclosures emphasize a combination of clinical development, preclinical research, and regulatory interactions as core elements of its approach to advancing therapies for liver and viral diseases.

Stock and governance information

Aligos’ SEC filings indicate that its common stock has a par value of $0.0001 per share and is registered under Section 12(b) of the Securities Exchange Act of 1934. The company has amended its Amended and Restated Certificate of Incorporation to increase the number of authorized shares of voting and non-voting common stock, reflecting its capital structure needs as a publicly traded biotechnology issuer. Stockholders vote on matters such as director elections, auditor ratification, equity plan amendments, and changes to authorized share counts at annual meetings, as documented in its Form 8-K filings.

Through its public communications and regulatory filings, Aligos presents itself as a clinical stage biotechnology company with a focused pipeline in liver and viral diseases, a lead HBV program (pevifoscorvir sodium) in Phase 2 development, and additional candidates in obesity, MASH, and nucleic acid-based approaches for HBV and HDV.

Stock Performance

$1.26
-3.08%
-0.04
After hoursChange vs the $1.30 closeLast updated: at
-83.6%
Performance 1 year

Aligos Therapeutics (ALGS) closed at $1.30 on November 18, 2026. Over the past 12 months, the price has lost 83.6%.

See what a $1,000 investment in ALGS would be worth today

Average down calculator for ALGS

ALGS Metrics & Rankings

Price returns through November 18, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Aligos Therapeutics has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include earnings, clinical trial, earnings date. View all ALGS news →

Financial Highlights

Aligos Therapeutics generated $2.2M in revenue in FY2025, operating income reached -$88.0M, and net income was -$24.2M. Diluted earnings per share stood at -$2.45. The company generated -$82.5M in operating cash flow. The current ratio was 3.90, measuring current assets divided by current liabilities.

$2.2M
Revenue (FY2025)
-$24.2M
Net Income (FY2025)
-$82.5M
Operating Cash Flow

Upcoming Events

DEC
09
December 9, 2026 Corporate

25% options vest

25% of 14,100 inducement stock options vest on one-year anniversary
YEAR
2027
2027 Clinical

Phase 2 topline data release

Topline Phase 2 B-SUPREME data release for pevifoscorvir sodium; expected during 2027; timing depends on enrollment.
YEAR
2027
2027 Clinical

B-SUPREME topline readout 2027

Phase 2 B-SUPREME topline data readout for chronic HBV trial
YEAR
2027
2027 Clinical

Topline Phase 2 data

Topline results from Phase 2 B-SUPREME study (HBeAg- and HBeAg+ cohorts)
JAN
29
January 29, 2027 Corporate

25% options vest

25% of 81,100 options vest for new hires under 2024 Inducement Plan.
JAN
29
January 29, 2027 - January 29, 2030 Corporate

Remaining options vest monthly

Remaining 75% vests monthly over three years under the Inducement Plan.
APR
22
April 22, 2027 Corporate

25% option vesting

25% of 10,700 inducement options vest for new hires; exercise price equals closing price on grant date 2026-04-22.
APR
22
April 22, 2027 - April 22, 2030 Corporate

Monthly option vesting

Remaining 75% of 10,700 options vest monthly from 2027-04-22 through 2030-04-22; exercisable at the grant date closing price.
Q3
2027
Q3 2027 Clinical

B-SUPREME topline data

Topline data from Phase 2 B-SUPREME (131 HBeAg+,114 HBeAg-) expected in late Q3 2027; company to announce release/webcast.
Q3
2027
Q3 2027 Clinical

B-SUPREME topline results

Topline Phase 2 B-SUPREME results expected late Q3 2027 for HBeAg-positive and -negative cohorts; investor update anticipated.
SEP
2027
September 2027 Clinical

Topline data release

Topline Phase 2 data for B-SUPREME (pevifoscorvir sodium) in chronic HBV expected late Q3 2027; no webcast.
DEC
09
December 9, 2029 Corporate

Options fully vest

Remaining options vest monthly; full vesting completes on four-year anniversary

Aligos Therapeutics has 12 upcoming scheduled events. The next event, "25% options vest", is scheduled for December 9, 2026 (in 20 days). Investors can track these dates to stay informed about potential catalysts that may affect the ALGS stock price.

Short Interest History

Last 12 Months

Short interest in Aligos Therapeutics (ALGS) currently stands at 677.2 thousand shares, down 4.3% from the previous reporting period, representing 13.9% of the float. Since November 2025, short interest has increased by 199.1%.

Days to Cover History

Last 12 Months

Days to cover for Aligos Therapeutics (ALGS) currently stands at 20.8 days. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 649.8%. Across the settlements charted above, it has ranged from 1.0 to 21.7 days.

ALGS Company Profile & Sector Positioning

Aligos Therapeutics (ALGS) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing ALGS often look at related companies in the same sector, including Neuphoria Therapeutics Inc. (NEUP), Passage Bio, Inc. (PASG), Dare Bioscience, Inc. (DARE), BioCardia, Inc. (BCDA), and Chemomab Therapeutics Ltd. (CMMB). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ALGS's relative position within its industry.

Frequently Asked Questions

The current stock price of Aligos Therapeutics (ALGS) is $1.26 in after-hours trading as of November 18, 2026.

The market cap of Aligos Therapeutics (ALGS) is approximately $7.9M. Learn more about what market capitalization means .

The FY2025 revenue of Aligos Therapeutics (ALGS) is $2.2M, from its most recent completed fiscal year.

The FY2025 net income of Aligos Therapeutics (ALGS) is -$24.2M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Aligos Therapeutics (ALGS) is -$2.45 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Aligos Therapeutics (ALGS) is -$82.5M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Aligos Therapeutics (ALGS), current assets divided by current liabilities, was 3.90 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Aligos Therapeutics (ALGS) is -$88.0M for FY2025, its most recent completed fiscal year. Learn about operating income.

Aligos Therapeutics, Inc. is a clinical stage biotechnology company focused on improving patient outcomes by developing best-in-class therapies for liver and viral diseases. Its publicly described areas of focus include chronic hepatitis B virus infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.

Pevifoscorvir sodium, also referred to as pevy and formerly known as ALG-000184, is an oral small molecule capsid assembly modulator (CAM-E) under investigation by Aligos for the treatment of chronic hepatitis B virus infection. Phase 1 studies have evaluated its antiviral activity and tolerability, and a Phase 2 trial called B-SUPREME is comparing pevifoscorvir sodium monotherapy with tenofovir disoproxil fumarate in untreated HBeAg-positive and HBeAg-negative adults with chronic HBV.

ALG-055009 is described by Aligos as a potent thyroid hormone receptor beta (THR-β) agonist under development for obesity and metabolic dysfunction-associated steatohepatitis (MASH). In nonclinical diet-induced obese mouse models, ALG-055009 combined with incretin receptor agonists such as semaglutide or tirzepatide produced synergistic body weight loss compared with monotherapy, primarily through additional fat mass reduction.

Aligos targets liver and viral diseases, with a focus on chronic hepatitis B virus infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses. It also reports preclinical work on antisense oligonucleotide strategies for hepatitis B and hepatitis delta virus, and siRNA molecules targeting human HSD17beta13 for MASH.

Aligos Therapeutics, Inc. lists its common stock on The Nasdaq Stock Market LLC (Nasdaq Capital Market). The company’s ticker symbol is ALGS, and its common stock has a par value of $0.0001 per share as disclosed in SEC filings.

Aligos describes the Phase 2 B-SUPREME study of pevifoscorvir sodium as a randomized, double-blind, active-controlled, multicenter trial in untreated HBeAg-positive and HBeAg-negative adults with chronic HBV infection. The study compares pevifoscorvir sodium monotherapy with tenofovir disoproxil fumarate and evaluates virologic endpoints such as HBV DNA below the lower limit of quantification, along with safety, pharmacokinetics, and additional HBV biomarkers.

In addition to pevifoscorvir sodium and ALG-055009, Aligos reports early-stage and preclinical programs that include antisense oligonucleotide strategies targeting HBV and hepatitis delta virus, as well as preclinical siRNA molecules targeting human HSD17beta13 for the treatment of metabolic dysfunction-associated steatohepatitis. These programs have been the subject of poster presentations at scientific meetings.

Aligos has disclosed a 2020 Incentive Award Plan and subsequent amendments to increase the number of shares reserved under the plan, along with a 2024 Inducement Plan used for equity awards to new employees under Nasdaq Listing Rule 5635(c)(4). The company grants non-qualified stock options under these plans, with vesting schedules that typically extend over several years, as part of its approach to attracting and retaining employees.

Aligos Therapeutics, Inc. reports in its SEC filings that its principal offices are located in South San Francisco, California. The company is incorporated in the state of Delaware.

Aligos disseminates information about its clinical and preclinical data through press releases, presentations at scientific and medical conferences such as AASLD’s The Liver Meeting and HEP-DART, and related materials that it makes available in its posters and presentations resources. The company also files reports and current reports with the U.S. Securities and Exchange Commission.